Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272338 | 0.87 | MLYCD (0.45) | HPGDMEN1KMT2AMLYCDSMN1; SMN2 | |
| SCHEMBL4843412 | 0.84 | MLYCD (0.49) | HPGDKMT2AMLYCDSMN1; SMN2NPC1 | |
| SCHEMBL38651975 | 0.83 | ESR1 (0.47) | HPGDMEN1KMT2AMLYCDRAB9A | |
| SCHEMBL20982522 | 0.83 | MLYCD (0.45) | HPGDMEN1KMT2ATSHRMLYCD | |
| SCHEMBL13552071 | 0.82 | HPGD (0.67) | HPGDMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL17025506 | 0.82 | MLYCD (0.44) | HPGDMEN1KMT2ATSHRMLYCD | |
| SCHEMBL14720018 | 0.82 | MLYCD (0.48) | HPGDMEN1KMT2ATSHRMLYCD | |
| SCHEMBL31680241 | 0.82 | MLYCD (0.48) | HPGDMEN1KMT2ATSHRMLYCD | |
| SCHEMBL15884157 | 0.82 | ALDH1A1 (0.65) | HPGDMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL185480 | 0.82 | MEN1 (0.48) | HPGDMEN1KMT2ATSHRMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | KURA ONCOLOGY, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118063470-A | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| CN-111542526-B | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | WUXI APPTEC (HONG KONG) LIMITED (CN) | 2023-10-12 | — | — | US | disclosed |
| WO-2023102378-A1 | MACROCYCLIC COMPOUNDS HAVING FARNESYLTRANSFERASE INHIBITORY ACTIVITY | KURA ONCOLOGY, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | RYR2, RYR1, GABRR1 | HPGD 899/4885MEN1 1730/4885KMT2A 4461/4885 |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | HPGD 2661/4885MEN1 1547/4885KMT2A 2694/4885 |
| US-12018011-B2 | Macrocyclic compounds and compositions, and methods of preparing and using the same | FNTA, FDPS, GGPS1 | HPGD 1382/4885MEN1 72/4885KMT2A 4281/4885 |
| US-20230322711-A1 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | FNTA, FDPS, GGPS1 | HPGD 1382/4885MEN1 72/4885KMT2A 4281/4885 |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | HPGD 1620/4885MEN1 2541/4885KMT2A 3991/4885 |
| US-20220213107-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | HPGD 2661/4885MEN1 1547/4885KMT2A 2694/4885 |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | HPGD 1620/4885MEN1 2541/4885KMT2A 3991/4885 |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | HPGD 2036/4885MEN1 1658/4885KMT2A 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.